Updated IASLC - Virtual Tumor Board On SCLC

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the management of small-cell lung cancer using a virtual tumor board format. SCLC is an aggressive subtype of lung cancer and for patients with advanced, or extensive-stage disease, the current first-line standard of care is chemo-immunotherapy. In the US and in Europe, the approved options are platinum and etoposide with a PDL1 inhibitor: either atezolizumab based on the IMpower 133 trial or durvalumab based on the CASPIAN trial.